O-RAN-ALLIANCE
22.10.2021 09:38:11 CEST | Business Wire | Press release
O-RAN ALLIANCE has released another set of technical specifications for open RAN published since July 2021. Initial versions of nine technical specifications comprise:
- O-RAN Non-Real-Time RAN Intelligent Controller (RIC) Architecture
- Near-Real-Time RIC and E2 Interface: Use Cases and Requirements v1.0
- O-RAN E2 Service Model: RAN Control (E2SM-RC) v1.0
- O-RAN O1 Interface specification for O-CU-UP and O-CU-CP towards the Service Management and Orchestration (SMO) framework
- O-RAN Acceleration Abstraction Layer FEC Profiles
- Infrastructure management services of the O2 interface
- O-Cloud Notification API Specification for Event Consumers
- O-RAN Xhaul Transport Testing Specification
- O-RAN Security Requirements Specifications
Another 39 technical documents bring extensions and new features to the existing specifications. All new specifications will soon be available on our website . To learn more, please read our blog post .
3rd O-RAN ALLIANCE Global Plugfest Underway with 77 companies at 7 venues
O-RAN ALLIANCE’s 3rd Global Plugfest has been in progress since summer 2021. 77 companies perform testing, integration or proofs of concept in 7 venues around the world. Technical work is planned to continue till the end of November 2021, with subsequent presentations of the results in our Plugfest Virtual Showcase .
18 demos of O-RAN technology prepared for MWC Los Angeles 2021 or the O-RAN Virtual Exhibition
Five O-RAN demonstrations are planned to be presented at the MWC Los Angeles 2021.
Parallel Wireless demonstrates its Open RAN, ALL G - 2G, 3G, 4G, and 5G, O-RAN compliant software platform showcasing an open, secure, and intelligent RAN architecture to deliver wireless connectivity, enabling people to be connected whenever, wherever, and however they choose. Visit the demo at South 2505Ex.
VMware Telco Cloud Platform RAN, powered by Dell EMC PowerEdge server and Intel FlexRAN, delivers flexibility to open RAN. The demo showcases the platform’s horizontal design and automation capabilities with 3 simple steps to deploy and programmatically provision the platform with Kubernetes to run Altiostar ’s vRAN functions. Visit the demo at Booth 1210.
VMware demonstrates the power of VMware RIC SDKs, enabling its partners to accelerate the development of their xApp/rApp; creating a vibrant application ecosystem. We bring the intelligence and innovation to the RAN faster. Visit the demo at Booth 1210.
Northeastern University showcases how Colosseum can be used to (i) instantiate a fully programmable end-to-end network controlled by O-RAN-compliant near-real-time RIC; (ii) collect performance datasets from the RAN, and (iii) implement AI-based control of the RAN through xApps and programmable software stacks. Visit the demo at Booth 1444.
Cohere Technologies and VMware demonstrate how Cohere’s 5G MU-MIMO Spectrum Multiplier xApp running on VMware RIC controls multiple UEs simultaneously in the same time and frequency slots to drastically boost capacity. Visit us to learn how we successfully demonstrated these technologies to a major European operator. Visit the demo at Booth 1210.
13 more virtual demos for MWC Los Angeles 2021 have enriched the O-RAN Virtual Exhibition :
MiTAC demonstrates a private 5G E2E O-RAN solution with O1 Interface based on 3rd Generation Intel® Xeon® Scalable Processors and integrated with an indoor O-RU which supports MIMO and 4T4R via Open Front Haul Interface.
CIG and partners demonstrate an open 5G small cell solution. The E2E solution comprises O-CU and O-DU in one O-DU box, with L2/L3 SW, L1 SW and HW from different vendors. Both O-DU and O-RU are designed with COTS components and open interfaces. A fronthaul gateway is also available as part of the open solution.
IPLOOK demonstrates a full stack cloud-native and container-based system of end-to-end 4G/5G converged mobile core solution for operators and enterprises.
STL demonstrated 5G Small Cell Split 7.2 O-RU (GARUDA) Interworking with ASOCS 5G NR SA Evaluation Kit (Cyrus 2.0), based on O-RAN IoT profiles. The setup included STL O-RU and ASOCS EVK (DU, CU, Core VM and CPE). The scenarios demonstrated PDU session establishment (registration procedure), followed by CUS-plane and M-plane connectivity.
University of Utah showcases O-RAN-based, xApp-controlled RAN slicing using the experiment workflows in the POWDER platform. We combine O-RAN with an open-source mobility stack, provide a top-to-bottom RAN application via the RIC, and deploy in a realistic wireless environment. This software is open-source and packaged in POWDER to enable further experimentation.
IS-Wireless showcases the next level of software disaggregation in 5G OpenRAN with protocol layers working as independent VNFs on various computing platforms: O-DU VNF/CNF on Edge Cloud (COTS HW), O-CU VNF on Core/Regional Cloud. The company achieved E2E connectivity on 5G with split option 7.2 and option 2.
Dell Technologies is working with an open ecosystem of partners to develop validated solutions. Together with Intel, VMware, Mavenir, Dell has developed a cloud-native Open RAN reference architecture available as a technology preview. The reference architecture offers a complete solution deployed on Dell EMC PowerEdge XR11, XR12 and R750 servers.
Rohde & Schwarz provides an explanation and demo about the measurement of roundtrip latency on IP layer in O-RAN and legacy networks. The IP layer is the basis for the application layer latency. Real-time and interactive applications are rapidly increasing. These applications need to be supported by 5G and other technologies. A latency comparison over different network types can be achieved.
VIAVI demonstrates the power of test case libraries to accelerate validation of disaggregated network performance, interoperability and security according to O-RAN defined test specifications. The TM500 UE Emulator Test Case Libraries leverage unmatched TM500 functional coverage and VIAVI expertise. Network performance is validated using extensive KPI monitoring and automated log analysis to quickly indicate compliance with the O-RAN test specifications.
Keysight and Auray partner in Auray OTIC and Security Lab for Certification and Badging of O-RAN solutions by performing Conformance Test, IOT Test and E2E Test services based on corresponding test solutions with a comprehensive mechanism ensuring openness, interoperability and conformity of O-RAN solutions from ecosystem players for both operators and vendor community.
Keysight Technologies showcases the Performance Benchmarking Solution (PBM) that directly controls Real UEs across device models and chipsets to automatically conduct tests as defined in TIFG E2E test specifications in both lab and field in a multi-vendor O-RAN environment.
CMCC and Inspur demonstrate a QoE assurance application deployed on the Near-RT RIC, providing the capabilities of QoE aware and intelligent RAN Control by collecting RAN measurements as well as sending control command (e.g., maximum MCS configuration) through E2 interface. This demo is validated in some industry scenarios.
Juniper Networks and VIAVI Solutions demonstrate successful transport of Open Fronthaul over a packet-switched network. Juniper's ACX Series routers, used as CSR/HSR, provide fronthaul transport connectivity. VIAVI's O-RU and O-DU emulators generate O-RAN compliant Open Fronthaul traffic (CU and M-plane), while VIAVI’s MTS-5800 fronthaul tester verifies the fronthaul transport/sync network.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211022005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
